Intocell Co., Ltd.

Intocell Co., Ltd. is a biotechnology company specializing in the development of antibody-drug conjugate (ADC) platform technologies. Based in Daejeon, South Korea and founded in 2015, the company focuses on creating innovative linkers, payloads, and conjugation methods designed to improve the effectiveness and safety of targeted cancer therapies. Intocell’s core technology includes proprietary scaffold moieties, ligands, toxins, and advanced linker chemistries, notably its OHPAS linker and novel benzodiazepine payloads engineered to address the limitations of traditional ADC toxins, such as poor solubility and functionalization challenges. By advancing its ADC platform, Intocell plays an important role in supporting pharmaceutical and biotech firms in the development of next-generation targeted therapeutics, contributing to the broader pharmaceuticals and biotechnology sector's efforts to enhance precision medicine and cancer treatment options. The company’s innovations position it as a key participant within the biotechnology industry, particularly in the fast-evolving field of oncology drug development.